Virtual Screening Approach to Identifying a Novel and Tractable Series of


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
11 Feb 2021
Historique:
received: 16 10 2020
accepted: 12 01 2021
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 20 2 2021
Statut: epublish

Résumé

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is

Identifiants

pubmed: 33603968
doi: 10.1021/acsmedchemlett.0c00554
pmc: PMC7883467
doi:

Types de publication

Journal Article

Langues

eng

Pagination

217-227

Informations de copyright

© 2021 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Antimicrob Agents Chemother. 2011 Jun;55(6):2670-8
pubmed: 21444693
ChemMedChem. 2016 Jan 5;11(1):15-21
pubmed: 26603496
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Respir Med. 2017 Jul;128:1-6
pubmed: 28610665
Chem Commun (Camb). 2013 Apr 21;49(31):3197-9
pubmed: 23482955
J Cyst Fibros. 2007 Jan;6(1):57-65
pubmed: 16870510
J Med Chem. 2000 Feb 10;43(3):305-41
pubmed: 10669559
Jpn J Exp Med. 1978 Feb;48(1):81-4
pubmed: 97425
Front Microbiol. 2019 Aug 02;10:1701
pubmed: 31428062
ACS Med Chem Lett. 2012 Aug 9;3(8):668-672
pubmed: 23181168
Sci Rep. 2015 Apr 23;5:9936
pubmed: 25905792
J Med Chem. 2007 Jan 11;50(1):74-82
pubmed: 17201411
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Clin Microbiol Rev. 2011 Jan;24(1):29-70
pubmed: 21233507
J Med Chem. 1989 Aug;32(8):1988-96
pubmed: 2666669
Chem Biol. 2015 Apr 23;22(4):483-491
pubmed: 25892201
Eur J Clin Microbiol Infect Dis. 2013 Oct;32(10):1231-52
pubmed: 23619573
Chem Biol Drug Des. 2006 May;67(5):370-2
pubmed: 16784462
BMC Med. 2011 Apr 04;9:32
pubmed: 21463524

Auteurs

Simon Leiris (S)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

David T Davies (DT)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Nicolas Sprynski (N)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Jérôme Castandet (J)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Lilha Beyria (L)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Michael S Bodnarchuk (MS)

Charles River Laboratories, Harlow CM19 5TR, U.K.

Jonathan M Sutton (JM)

Charles River Laboratories, Harlow CM19 5TR, U.K.

Toby M G Mullins (TMG)

Charles River Laboratories, Harlow CM19 5TR, U.K.

Mark W Jones (MW)

Charles River Laboratories, Harlow CM19 5TR, U.K.

Andrew K Forrest (AK)

Charles River Laboratories, Harlow CM19 5TR, U.K.

T David Pallin (TD)

Charles River Laboratories, Harlow CM19 5TR, U.K.

Paduri Karunakar (P)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Sathish Kumar Martha (SK)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Battu Parusharamulu (B)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Ramesh Ramula (R)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Venkatesh Kotha (V)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Narender Pottabathini (N)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Srinivasu Pothukanuri (S)

GVK Biosciences Private Limited, Plot No. 28 A, IDA Nacharam, Hyderabad 500076, India.

Marc Lemonnier (M)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Martin Everett (M)

Antabio SAS, 436 rue Pierre et Marie Curie, 31670 Labège, France.

Classifications MeSH